Let’s start up with the current stock price of Adverum Biotechnologies Inc. (ADVM), which is $0.82 to be very precise. The Stock rose vividly during the last session to $0.8199 after opening rate of $0.77 while the lowest price it went was recorded $0.7315 before closing at $0.79.Recently in News on February 27, 2023, Adverum Biotechnologies to Present at Upcoming Investor Conferences. Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:. You can read further details here
Adverum Biotechnologies Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.8200 on 07/14/22, with the lowest value was $0.5310 for the same time period, recorded on 12/27/22.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Adverum Biotechnologies Inc. (ADVM) full year performance was -33.43%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adverum Biotechnologies Inc. shares are logging -55.01% during the 52-week period from high price, and 54.20% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.53 and $1.82.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 790291 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Adverum Biotechnologies Inc. (ADVM) recorded performance in the market was 41.29%, having the revenues showcasing 28.84% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 83.75M, as it employees total of 188 workers.
Market experts do have their say about Adverum Biotechnologies Inc. (ADVM)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.6999, with a change in the price was noted -0.04. In a similar fashion, Adverum Biotechnologies Inc. posted a movement of -4.23% for the period of last 100 days, recording 511,533 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADVM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Adverum Biotechnologies Inc. (ADVM)
Raw Stochastic average of Adverum Biotechnologies Inc. in the period of last 50 days is set at 92.35%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 90.94%. In the last 20 days, the company’s Stochastic %K was 83.86% and its Stochastic %D was recorded 82.15%.
Bearing in mind the latest performance of Adverum Biotechnologies Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 41.29%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -22.75%, alongside a downfall of -33.43% for the period of the last 12 months. The shares increased approximately by -1.10% in the 7-day charts and went down by 31.49% in the period of the last 30 days. Common stock shares were driven by 28.84% during last recorded quarter.
